185 related articles for article (PubMed ID: 8879230)
1. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice.
Screpanti I; Musiani P; Bellavia D; Cappelletti M; Aiello FB; Maroder M; Frati L; Modesti A; Gulino A; Poli V
J Exp Med; 1996 Oct; 184(4):1561-6. PubMed ID: 8879230
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice.
Screpanti I; Romani L; Musiani P; Modesti A; Fattori E; Lazzaro D; Sellitto C; Scarpa S; Bellavia D; Lattanzio G
EMBO J; 1995 May; 14(9):1932-41. PubMed ID: 7744000
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 and CAAT/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation.
Alonzi T; Gorgoni B; Screpanti I; Gulino A; Poli V
Immunobiology; 1997 Dec; 198(1-3):144-56. PubMed ID: 9442386
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
Nishi J; Maruyama I
Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
[TBL] [Abstract][Full Text] [Related]
5. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
Kinney MC; Hummell DS; Villiger PM; Hourigan A; Rollins-Smith L; Glick AD; Lawton AR
J Clin Immunol; 1994 Nov; 14(6):382-90. PubMed ID: 7883866
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 gene expression in Castleman's disease.
Leger-Ravet MB; Peuchmaur M; Devergne O; Audouin J; Raphael M; Van Damme J; Galanaud P; Diebold J; Emilie D
Blood; 1991 Dec; 78(11):2923-30. PubMed ID: 1954381
[TBL] [Abstract][Full Text] [Related]
7. Multicentric Castleman's disease in association with a solitary plasmacytoma: a case report.
Gould SJ; Diss T; Isaacson PG
Histopathology; 1990 Aug; 17(2):135-40. PubMed ID: 2227838
[TBL] [Abstract][Full Text] [Related]
8. A case of multicentric Castleman's disease demonstrating severe eosinophilia and enhanced production of interleukin-5.
Ishii T; Tatekawa T; Koseto M; Ishii M; Kobayashi H; Koike M; Fujii T; Saeki Y
Eur J Haematol; 2003 Feb; 70(2):115-8. PubMed ID: 12581193
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
[TBL] [Abstract][Full Text] [Related]
10. Castleman's disease associated with myasthenia gravis.
Day JR; Bew D; Ali M; Dina R; Smith PL
Ann Thorac Surg; 2003 May; 75(5):1648-50. PubMed ID: 12735602
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6-producing giant cell carcinoma of the lung with multicentric Castleman's disease-like presentation.
Higashikuni Y; Mori M; Kino H
Intern Med; 2007; 46(10):669-73. PubMed ID: 17527041
[TBL] [Abstract][Full Text] [Related]
12. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease.
Parravicini C; Corbellino M; Paulli M; Magrini U; Lazzarino M; Moore PS; Chang Y
Am J Pathol; 1997 Dec; 151(6):1517-22. PubMed ID: 9403701
[TBL] [Abstract][Full Text] [Related]
13. A benign course of multicentric Castleman's disease with involvement of the spleen and bone marrow.
Levo Y; Behar AJ; Blum I; Frish B
Eur J Haematol; 1987 Nov; 39(5):471-4. PubMed ID: 3691764
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type.
Ohyashiki JH; Ohyashiki K; Kawakubo K; Serizawa H; Abe K; Mikata A; Toyama K
Am J Clin Pathol; 1994 Mar; 101(3):290-5. PubMed ID: 8135184
[TBL] [Abstract][Full Text] [Related]
15. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.
Otani K; Inoue D; Fujikura K; Komori T; Abe-Suzuki S; Tajiri T; Itoh T; Zen Y
Oncotarget; 2018 Jan; 9(6):6691-6706. PubMed ID: 29467920
[TBL] [Abstract][Full Text] [Related]
18. Castleman's disease: a study of a rare lymphoproliferative disorder in a university hospital.
Al-Amri AM; Abdul-Rahman IS; Ghallab KQ
Gulf J Oncolog; 2010 Jan; (7):25-36. PubMed ID: 20164006
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
Nishi J; Arimura K; Utsunomiya A; Yonezawa S; Kawakami K; Maeno N; Ijichi O; Ikarimoto N; Nakata M; Kitajima I; Fukushige T; Takamatsu H; Miyata K; Maruyama I
Br J Haematol; 1999 Mar; 104(3):482-5. PubMed ID: 10086783
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.
Yoshizaki K; Matsuda T; Nishimoto N; Kuritani T; Taeho L; Aozasa K; Nakahata T; Kawai H; Tagoh H; Komori T
Blood; 1989 Sep; 74(4):1360-7. PubMed ID: 2788466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
